Search tips
Search criteria 


Logo of plosonePLoS OneView this ArticleSubmit to PLoSGet E-mail AlertsContact UsPublic Library of Science (PLoS)
PLoS One. 2012; 7(11): e50111.
Published online 2012 November 20. doi:  10.1371/journal.pone.0050111
PMCID: PMC3502352

Structural Organization of Mammalian Prions as Probed by Limited Proteolysis

Ilia V. Baskakov, Editor


Elucidation of the structure of PrPSc continues to be one major challenge in prion research. The mechanism of propagation of these infectious agents will not be understood until their structure is solved. Given that high resolution techniques such as NMR or X-ray crystallography cannot be used, a number of lower resolution analytical approaches have been attempted. Thus, limited proteolysis has been successfully used to pinpoint flexible regions within prion multimers (PrPSc). However, the presence of covalently attached sugar antennae and glycosylphosphatidylinositol (GPI) moieties makes mass spectrometry-based analysis impractical. In order to surmount these difficulties we analyzed PrPSc from transgenic mice expressing prion protein (PrP) lacking the GPI membrane anchor. Such animals produce prions that are devoid of the GPI anchor and sugar antennae, and, thereby, permit the detection and location of flexible, proteinase K (PK) susceptible regions by Western blot and mass spectrometry-based analysis. GPI-less PrPSc samples were digested with PK. PK-resistant peptides were identified, and found to correspond to molecules cleaved at positions 81, 85, 89, 116, 118, 133, 134, 141, 152, 153, 162, 169 and 179. The first 10 peptides (to position 153), match very well with PK cleavage sites we previously identified in wild type PrPSc. These results reinforce the hypothesis that the structure of PrPSc consists of a series of highly PK-resistant β-sheet strands connected by short flexible PK-sensitive loops and turns. A sizeable C-terminal stretch of PrPSc is highly resistant to PK and therefore perhaps also contains β-sheet secondary structure.


Prions are the etiological agents responsible for a diverse set of transmissible fatal neurodegerative diseases of humans and animals, characterized by an abnormal accumulation of prion protein (PrP) [1], [2], primarily in the brain. Prions replicate by converting the normal non-infectious cellular prion protein (PrPC) into a prion (PrPSc), via a poorly characterized post-translational conformational transformation. In mice, PrP contains approximately 209 amino acids (numbered 23–231 after cleavage of a 22–mer signal peptide) and has four covalent post-translational modifications: two asparagine N-linked glycans at residues N180 and N196, a disulfide bridge between residues C178–C213 and a glycosylphosphatidylinositol (GPI) anchor attached to the C-terminus of the protein (residue S231) [2], [3]. Mouse PrPC is a monomer, while PrPSc is a heterogeneous multimer [2], [3]. There have been no demonstrated covalent differences between mouse PrPSc and PrPC. The only difference between PrPSc and PrPC is conformational; they are isoforms [2].

The structure of folded, monomeric, recombinant PrP, highly likely to be identical to that of PrPC, has been solved by NMR spectroscopy [4] and X-ray crystallography [5]. In contrast, the structure of PrPSc remains unclear because the insolubility of PrPSc and the failure to crystallize the heterogeneous PrPSc multimers prevent the application of the mentioned high resolution analytical techniques. However, a variety of lower resolution instrumental techniques have provided some information about the structure of PrPSc. Unlike PrPC, PrPSc is partially resistant to proteinase K (PK) digestion [2], [6]. The secondary structure of PrPC is largely composed of unstructured and α-helical regions, while PrPSc is largely composed of β-sheet with little, if any, α-helix [7], [8], [9]. The structure of PrPSc has also been studied using electron microscopy-based analysis of two-dimensional crystals of the PK resistant core of Syrian hamster (SHa) PrPSc (PrP27–30) [10], [11] and mass spectrometry(MS)-based analysis of hydrogen/deuterium exchange [9]. Although theoretical models for PrPSc have been proposed [10], [12], there is an insufficient amount of experimental data to reach a definitive consensus.

In a previous study, we used limited proteolysis to elucidate structural features of PrPSc [13]. Conformational parameters such as surface exposure of amino acids, flexibility, and local interactions correlate well with limited proteolysis. Peptide bonds located within β-strands are resistant to proteolytic cleavage, whereas peptide bonds within loops and, more rarely, α-helices may be cleaved [14]. Therefore, the targets for limited proteolysis are locally unfolded or highly flexible segments [14]. In our previous study [13], we demonstrated the usefulness of combining limited proteolysis and mass spectrometry (MS) to obtain structural information about two strains of hamster PrPSc. We concluded that the amino-terminal half of PrPSc features a series of short PK-resistant stretches, presumably β-strands, interspersed with short PK-sensitive stretches, likely loops and turns. Unfortunately, the structural information was largely limited to the N-terminal portion of the protein, as a consequence of the covalent attachment of the heterogeneous GPI anchor and the heterogeneous asparagine-linked sugar antennae to amino acids in the C-terminal portion of the molecule, which prevented MS-based analysis of this part of the molecule.

Here we extended our studies of the structure of PrPSc, by using transgenic (tg) mice expressing PrPC lacking the GPI anchor (GPI) [15]. The GPI PrPSc produced by these mice is fully infectious, lacks the GPI anchor, and is largely unglycosylated, which reduces the heterogeneity in the C-terminal portion of the molecule [15], [16]. These properties make it ideal to carry out structural studies, and have allowed us to obtain, for the first time, a complete survey of the whole PrPSc sequence, regarding its susceptibility to proteolysis.


Accumulation of PrPSc in GPI-anchorless Mice

Homozygous GPI-anchorless PrP mice were inoculated at 6 weeks of age with the RML strain of murine-adapted scrapie. Three-hundred sixty-five days post-inoculation, the mice were humanely euthanized. Their brains were surgically removed for further biochemical processing. The presence of PrPSc was confirmed by digesting a portion of some of these brains, after suitable homogenization, with proteinase K (PK) and analyzing the result by Western blot (Figure 1A and S1). The PK treatment yielded the characteristic PK resistant core protein, referred to as PrP27-30 in PK-treated wild-type PrPSc, although in this case its apparent MW is lower, given the lack of GPI and sugars. Histological analysis of brains from several of the infected transgenic mice showed a characteristic PrP accumulation pattern, as previously described [15], [16], with hyaline deposits arranged radially around blood vessels. Those deposits were strongly immunoreactive to PrP monoclonal antibody 6H4. Deposits were also located submeningeally, subventricularly and scattered in the neuropil (Figure 1B). In order to verify that the GPI- PrPSc was infective, a group of ten wild-type (C57BL/6) mice were inoculated with brain homogenate prepared from one of the infected transgenic mice. All ten of these wild-type mice became ill with clinical signs characteristic of the RML strain of murine-adapted scrapie and were humanely euthanized. The incubation period of the disease was 154±15 days post-inoculation (Figure 1C).

Figure 1
Characterization of GPI- PrPSc. A.

Identification of PK Cleavage Sites in GPI-anchorless PrPSc by Mass Spectrometric Detection

We isolated PK-resistant PrPSc fragments from infected GPI brains. Purity of this material was assessed by SDS-PAGE followed by Coomassie staining (Figure S2). Using a high resolution Tricine/SDS-PAGE system [17], we compared the distribution of these fragments with that of fragments present in PK-treated unpurified GPI infected brain homogenate, and found them to be similar, which demonstrates that our purification process isolates all of the PK-resistant fragments (Figure S3). GPI PrPSc, unlike wild-type PrPSc, permits the use of MS to accurately identify all PK cleavage sites. This allowed us to analyze samples by Western blot (WB) and by MS.

We analyzed our samples with high mass accuracy using nano-LC-ESI-Qq-TOF MS (Figure S4) and identified three peaks of 17148, 16728, and 16371 Da (peptides G81-S232, G85-S232, and G89-S232). The smaller peptides were analyzed by MALDI-TOF. MS-based analysis revealed that the seven bands present in the WB (vide infra) contained thirteen peptides with MWs of 17148, 16726, 16371, 13606, 13463, 12173, 12041, 11171, 9687, 9573, 8358, 7436 and 6274 Da. By comparing the observed masses with those calculated from the mouse GPI- PrP sequence, we determined that they correspond to peptides G81-S232, G85-S232, G89-S232, A116-S232, G118-S232, M133-S232, S134-S232, G141-S232, N152-S232, M153-S232, Y162-S232, S169-S232 and V179-S232 (Figure 2 and Table 1). No C-terminally truncated peptides were observed in our MS or WB-based analysis (vide infra).

Figure 2
MALDI-TOF spectrum of PK-treated purified GPI
Table 1
PK-resistant fragments in GPI PrPSc.

Identification of PK Cleavage Sites in GPI-anchorless PrPSc by Western Blot

In parallel we used Tricine-SDS-PAGE [17] followed by WB to analyze the PK-digested GPI- PrPSc (Figure 3). When the WB was probed with the antibody #51 (epitope G92-K100), just one wide band (~17 kDa) was observed, suggesting a set of cleavage products near G89 with no C-terminally truncated fragments. A blot probed with the W226 antibody (epitope W144-N152), revealed three additional faint bands (~14.6, 13 and 12 kDa), suggesting three PK cleavage sites between the epitopes of these antibodies. Probing with the C-terminal R1 antibody (epitope Y225-S230) revealed three more bands (~10.2, 8 and 6.7 kDa), suggesting three additional cleavage sites near residues Y149, P164 and V175. These bands agree quite well with our MS-based analysis (vide supra). In order to exclude the possibility that the observed PK-resistant fragments are the result of the known preference of PK of certain amino acid residues, rather than structural constraints, we subjected a similar amount of freshly refolded, recombinant MoPrP to cleavage by PK. A concentration of PK much lower than that used with mouse GPI- PrPSc, 1 µg/ml, completely destroyed all PrP, leaving no PK-resistant fragments larger than 3.5 kDa (Figure S5). Only PK concentrations below 1 µg/ml yielded some partially resistant fragments, whose sizes do not match those of PK-treated GPI- PrPSc.

Figure 3
Western blot analysis of PK-resistant GPI

Kinetics of PK Digestion in GPI-anchorless PrPSc

We performed a PK-digestion time course to determine the relationship of these peptides to one another. A time-dependent reduction in intensity of all PK-resistant bands was observed (Figure 4). The intensities of the 17, 14.6, 13, 12, and 6.7 kDa bands decreased steadily over time. By 240 minutes the intensities of the 17 and 10.2 kDa bands are nearly equal and by 360 minutes the intensity of the 17, 10.2 and 8 kDa bands are similar. These results are consistent with a progressive digestion of GPI- PrPSc from the N-terminus. This further suggests that different PK-resistant fragments are not from different sub-populations of GPI- PrPSc, instead they are derived from a larger common GPI- PrPSc peptide.

Figure 4
Kinetics of PK digestion of unpurified GPI

PK Cleavage Analysis After Partial Unfolding of GPI-anchorless PrPSc

The above observations were confirmed when the GPI PrPSc was partially unfolded with increasing concentrations of guanidine prior to PK cleavage, following the procedure of Kocisko et al. [18]. These authors have shown that partial unfolding of PrPSc with up to 2.5–3 M guanidine is reversible upon dialysis. GPI- PrPSc became more susceptible to proteolytic digestion in a guanidine-concentration dependent manner. At concentrations above 1 M, the 10.2 and, to a lesser extent, 12 and 8 kDa bands (N152-S232/M153-S232, G141-S232, and Y162-S232) predominate. Above 3 M guanidine, which renders the unfolding irreversible [18], almost no PK-resistant material remains (Figure 5). These results mirror those of the PK time course (vide supra), i.e. all of the bands are derived from the progressive N-terminal digestion of a progenitor peptide. In their original report, Kocisko et al. identified in SHaPrPSc partially unfolded with guanidine, a highly stable PK-resistant core starts before position 143 and continues to the C-terminus [18]. Sajnani et al. also detected a resistant SHaPrPSc core starting at position 139/142 [13].

Figure 5
Western blot of PK-digested series of GPI PrPSc samples following partial unfolding by guanidine HCl.


We present a complete survey of susceptibility to limited proteolysis of a PrPSc strain (Figure S6). The map of PK-susceptible spots: 116–118, 133–134, 141, 152–153, 162, 169, and 179, strongly suggests regions corresponding to loops and turns, while nicks at 81, 85, and 89 signal the frontier between the structured C-terminal and unstructured N-terminal domains of PrPSc. Given the high proportion of β-sheet secondary sctructure derived from FTIR analyses, it is logical to conclude that PK- resistant stretches flanking these spots most likely are strands of β-sheet.

Our results are in excellent agreement with our previous studies of wild-type PrPSc [13]. Our experiments with two different SHaPrPSc strains showed the sequence stretches 23–86 (263K), 23–101 (Dy), 117–119, 131–142, and the region around 154 ( = mouse M153) to be sensitive to PK. In the present study, besides confirming these regions as being PK-sensitive, we identified three additional PK cleavage sites in the C-terminal region of GPI- PrPSc (Y162, S169 and V179).

We did not find evidence of any PK-resistant peptide with an N-terminus beginning beyond V179. This is not a consequence of technical limitations, since the Tricine-based SDS-PAGE allows identification of peptides as small as 3.5 kDa (Figure 3). Instead, either this region is completely resistant to PK, or no stable PK-resistant cores remain if PK cleaves beyond that point.

Our results also agree with several studies describing amino-terminally truncated PK-resistant peptides in human CJD PrPSc. Zou et al. described human CJD PrPSc PK-resistant C-terminal peptides spanning from positions 154/156 and 162/167 to the C-terminus [19]. These fragments are analogous to GPI- PrPSc peptides N152-S232/M153-S232 and Y162-S232, S169-S232, respectively. Zanusso et al. described two additional amino-terminally truncated human CJD PrPSc peptides (MW of 16/17 kDa) [20], analogous to the GPI- PrPSc peptides G141-S232 and M133-S232/S134-S232. Kocisko et al. used a C-terminal antibody (epitope 217-232) to demonstrate the presence of a number of amino-terminally truncated PK-resistant species in SHaPrPSc [18]. Using synthetic mouse prions, Bocharova et al. identified the regions beginning at 138/141, 152/153, and 162, and extending to the C-terminus as being resistant to PK [21]. This suggests that synthetic prions and PrPSc share key structural elements, which would explain the capacity of recombinant PrP fibrils to change their conformation, via a “deformed templating” mechanism, to that of PrPSc [22].

In contrast, relatively few C-terminally truncated peptides have been described. Notari et al. reported two human CJD PrPSc peptides truncated near position 228 [23]. Stahl et al. also reported the presence of a peptide truncated at position 228 in PK-treated SHaPrPSc [24]. The absence of such fragments in our study could be explained by slight differences in sample preparation, or perhaps by the fact that the absence of the GPI-anchor might have an effect on nearby residues.

This conspicuous absence of the C-terminally truncated peptides is a reflection of the stability of the C-terminal region, in GPI PrPSc appears to be the most stable part of the molecule, which is inconsistent with the presence of substantial stretches of α-helical secondary structure in that region. Our results agree with Smirnovas et al., who showed the C-terminus of GPI- PrPSc to exhibit extremely low rates of H/D exchange, typical of extensive H-bonding (β-sheet) [9]. These authors showed that an FTIR absorbance band (~1,660 cm−1) previously assigned to α-helical secondary structure in PrPSc is also present in the spectrum of recombinant PrP amyloid fibrils, which contain no α-helices, and therefore cannot be taken as evidence of the presence of α-helical structure. They concluded that GPI PrPSc consists of a series of β-sheet stretches connected by short loops and/or turns, in agreement with our conclusions. Some stretches exhibiting a somewhat higher exchange rate, suggested to overlap with loops/turns, such as 133–148 or 81–118, are consistent with flexible stretches identified in our study, although discrepancies also exist. The limited resolution of both analytical techniques prevents a more exhaustive comparison, but overall both of them agree.

GPI- PrPSc fibrils are about 3–5 nm wide ([25] and our unpublished results). This constraint means that each PrPSc monomer must be coiled in such a way as to fit approximately 140–145 residues (~G85–S232) into this width. To do so, PrPSc monomers must necessarily adopt a multi-layer architecture, as seen in SH3 fibers [26] or the HET-s fungal prion domain [27]. The HET-s prion domain packs 70 residues into two β-strands alternating with turns and loops [27]. Wille et al. have suggested that PrPSc fibrils are composed of four rungs of β-strands, based on their interpretation of X-ray diffraction patterns [28]. In this model, each rung would comprise ~36–37 residues. Positions N152-M153 lie near the middle of the G85-S232 sequence, so it is tempting to speculate that they might be located at an exposed position at the border between rungs. This might explain why the N152-S232 and/or M153-S232 fragment emerges as the most conspicuous PK-resistant fragment after prolonged treatment with PK or partial unfolding with guanidine (Figures 4 and and5).5). Positions A116-G118 might be the border between the two most amino-terminal rungs (approximately G85-A115 and A119-E151). On the other hand, our results are partially inconsistent with the location assigned by Govaerts et al., using threading algorithms, to residues K100-P104 and E145-R163, placed in loops and not rungs [10]. Our data show that the stretches formed by residues K100-P104, N142-E151, and Y154-Y161, are PK-resistant, i.e., likely part of a β-strand rung (Figure 2 and Table 1).

In summary, our data support a PrPSc structure consisting of a series of highly PK-resistant β-sheet strands interspersed with PK-sensitive short flexible loops and turns. Furthermore, the region comprising ~V179 to the C-terminus of PrPSc is probably composed primarily of β-sheet, as it is highly resistant to PK. Our data are consistent with our previous results (263K and Dy strains) and those of other researchers using SHaPrPSc. Furthermore, they are consistent with those observed for human CJD PrPSc, which suggests that the myriad human, hamster and mouse prions share a common basic structure.

Materials and Methods

Ethics Statement

Animal experiments were carried out in accordance with the European Union Council Directive 86/609/EEC. The procedures and animal care were governed by a protocol that was approved by the Institutional Ethics Committee of the University of Santiago de Compostela. All efforts were made to minimize the suffering of the animals.


Transgenic heterozygous GPI-anchorless (GPI-) PrP mice (tg44(+/−)) were a generous gift from Bruce Chesebro, Rocky Mountain Laboratories, NIH, Montana, USA. Mice were crossed to obtain homozygous GPI- animals (tg44−/−), which were identified by tail DNA analysis using the PCR protocol described by Chesebro et al. [15]. Homozygous animals were bred and expression of GPI- PrP confirmed by Western blot (Figure S1). Female mice were intracerebrally inoculated at six weeks of age with 20 µl of a 2% RML-infected mouse brain homogenate (BH), kindly provided by Juan María Torres, CISA, Madrid, Spain. After 365 days post inoculation, the asymptomatic mice [16] were euthanized, their brains surgically removed, rinsed in PBS, and stored at −80°C until needed.

Preparation of Brain Homogenates and Isolation of GPI-anchorless PrPSc

Mouse BH, 10% w/v, were prepared in PBS, 5% sarkosyl, using a dounce homogenizer (Wheaton Industries Inc, NJ, USA), followed by one pulse of sonication to clarify the homogenate, with an ultrasonic homogenizer probe (Cole Parmer Instrument CO., Chicago IL, USA).

GPI PrPSc was isolated using the method of Baron et al. [8]. During the purification, total PrPSc was treated with 10 µg/ml of proteinase K. The final GPI PrPSc pellet was resuspended in 100 µl of deionised water or in 20 µl of a 6 M guanidine solution (final concentration 1.75 µg/µl). The stock suspension was stored at 4°C. Its purity was assessed by Coomassie stained SDS-PAGE gel and estimated to be ~95% pure. The yield of GPI- PrPSc was ~35 µg per brain (BCA protein assay).

Recombinant PrP

Recombinant Mouse PrP(23-231) was expressed in E. coli, and purified and refolded in-column on an NTA affinity column (GE Healthcare, Uppsala, Sweden), as previously described [29]. Refolded protein was dialyzed against 10 mM sodium phosphate buffer pH 5.8 and then against d.i. water.

Limited Proteolysis

Aliquots of BH (10% in PBS, 5% Sarkosyl) were digested with PK (Sigma-Aldrich, St. Louis, MO, USA) in 20 mM Tris-HCl pH 8.5 at 37°C for 1 h unless otherwise stated. Digestion was stopped by addition of Pefabloc (Fluka, Buchs, Switzerland) to a final concentration of 2 mM. Deglycosylation was carried out with 2 µl of PNGase F solution (New England Biolabs, Ipswich, MA, USA) at 37°C for 48 h, according to the manufacturer’s instructions.

Digestion with PK After Partial Unfolding with Guanidinehcl (Gnd)

Samples of BH (5 µl) were mixed with an equal volume of an appropriate aqueous Gnd solution to yield the desired final Gnd concentration and then incubated at 37°C for 1 h. After incubating, the samples were diluted with buffer (20 mM Tris-HCl pH 8.5) to yield a 0.4 M Gnd solution, which were then treated with PK (25 µg/ml) for 1 h at 37°C. The digestion was stopped by adding Pefabloc (2 mM final concentration) and the protein was precipitated by addition of ice-cold methanol (85% final concentration). The resulting pellets were resuspended in 9 µl of deionized water, and deglycosylated with PNGase F (vide supra).

Tricine-SDS-PAGE and Western Blot Analysis

The precipitated pellets were boiled for 10 minutes in 10 µl of Tricine sample buffer (BioRad, Hercules, CA, USA) containing 2% (v/v) of β-mercaptoethanol. Electrophoresis was performed using precast 10–20% Tris-Tricine/Peptide gels (BioRad, Hercules, CA, USA), in the Criterion System (BioRad, Hercules, CA, USA). The cathode buffer was Tris-Tricine-SDS buffer 1 × (Sigma-Aldrich, St. Louis, MO, USA) and the anode buffer, 1 M Tris-HCl pH 8.9. Electrophoresis was performed at constant voltage (125 volts) for 200 minutes, on ice.

The gels were electroblotted (350 mA, for 150 minutes; 4°C) onto PVDF membranes (Immobilon-P, 0.45 µm; Millipore, Billerica, MA, USA). Membranes were probed with the following monoclonal antibodies: mAb #51 (epitope: G92-K100), undiluted; W226 (epitope: W144-N152), at 1[ratio]5000 dilution; or R1 (epitope: Y225-S230), at a 1[ratio]5000 dilution. Peroxidase-conjugated anti-mouse or anti-human antibodies (GE Healthcare, Little Chalfont, UK) were used as a secondary antibody, as appropriate (1[ratio]5000 dilution). Blots were developed with ECL-plus reagent (GE Healthcare, Little Chalfont, UK). Three sets of partially overlapping MW markers, Peptide Molecular Weight (Sigma-Aldrich, St. Louis, MO, USA), Kaleidoscope Prestained Standard (BioRad, Hercules, CA, USA) and Novex Sharp Protein Standard (Invitrogen, Carlsbad, CA, USA) were run in each analysis to calibrate the MW of the bands.

Mass Spectrometry

NanoLC/ESI/MS analysis was done with an Applied Biosystems (AB SCIEX, Framingham, MA) model QStar Pulsar equipped with a Proxeon Biosystems (Odense, Denmark) nanoelectrospray source. Samples of the Gnd stock solution (vide supra) were loaded automatically onto a C-18 trapping cartridge and chromatographed on a reversed-phase column (Vydac Everest 238EV5.07515, 75 mm × 150 mm) fitted with a coated spray tip (FS360-50-5-CE; New Objective, Inc.). A nanoflow LC system (Dionex, Sunnyvale, CA) with autosampler, column switching device, loading pump, and nanoflow solvent delivery system was used. Elution solvents were A (0.5% acetic acid in water) and B (0.5% acetic acid in 80% acetonitrile/20% water). Samples were eluted at 250 nL/min using a binary gradient (8% B at 0 min to 80% B in a 30 min linear gradient, held at 80% B for 5 min, then back to 8% B for 15 minutes). The QStar Pulsar was externally calibrated daily with human [Glu1]-fibrinopeptide B.

In parallel, 1 µL of the Gnd stock solution was mixed with with 49 µL of sinapinic acid (SA) solution (10 mg/mL SA dissolved in 30% ACN with 0.3% TFA) and analyzed by MALDI-TOF. One half µL aliquots were deposited using the dried-droplet method onto a 384 Opti-TOF MALDI plate (Applied Biosystems, Foster City, CA, USA). MALDI analysis was performed in a 4800 MALDI-TOF/TOF analyzer (Applied Biosystems, Foster City, CA, USA). MS spectra were acquired in linear mode (20 kV source) with a Nd:YAG, (355 nm) laser, and averaging 500 laser shots. The mass of the peptide M153-S232 (9573 Da) was determined by an iterative calibration approach, using insulin (m/z = 5733), ribonuclease A (m/z = 13682) and lysozyme (m/z = 14305), (Sigma-Aldrich, St. Louis, MO) as internal standards. Then, the signals from the M153-S232 (9573 Da), G89-S232 (16371 Da), and G81-S232 (17148 Da) peptides were used to calibrate the rest of peaks in the spectrum. Masses were matched to PrP fragments with the help of GPMAW 6.0 software (Lighthouse, Odense, Denmark).


Immediately after extraction, the brain was fixed in formalin and then sliced into four transversal sections by cutting the brain caudally and rostrally to the midbrain and at the level of the basal nuclei. The sections were dehydrated by equilibration in solutions of progressively higher ethanol concentration and then equilibrated with xylene before being embedded in paraffin. Haematoxylin-eosin was used to stain the 4 µm thick sections. Additional sections were mounted on 3-triethoxysilyl-propylamine-coated glass slides for immunohistochemical (IHC) studies.

These brain sections were deparaffinised, immersed in formic acid containing peroxidase inhibitors, and autoclaved prior to IHC analysis. These autoclaved samples were washed, treated with proteinase K, washed again, and then incubated overnight with the antibody 6H4 (1[ratio]2000, Prionics AG, Schlieren, Switzerland). The sections were developed using the DAKO EnVision system and 3,3′diaminobenzidine as the chromogenic substrate.

Supporting Information

Figure S1

Western blot of unpurified GPI PrPSc −/+ PK. Both samples were treated with PNGase F. WB was probed with the #51 antibody.


Figure S2

Characterization of isolated GPI PrPSc. 10 µl of sample were loaded and separated in a 15% gel by SDS-PAGE. The gel was stained by Coomassie blue. The molecular weight of the GPI-less PrP27-30 is ~16750 Da.


Figure S3

Western blot of PK-resistant fragments. In unpurified (1) and purified GPI- PrPSc (2). Both samples were digested with proteinase K, 25 µg/ml and 10 µg/ml, respectively, treated with PNGase F and resolved on a Tricine-SDS-PAGE gel. WB was probed with the R1 antibody.


Figure S4

Bayesian protein reconstruction of the nano-LC-ESI-MS spectra of PK-treated purified GPI PrPSc. The mass graphs of the three peaks: 17148 Da (top), 16729 Da (middle) and 16371 Da (bottom), identified by ESI-TOF are shown.


Figure S5

Western blot of recombinant MoPrP(23–231) cleavage by PK. Samples were digested with different concentrations of PK: 0, 0.2, 1, 5, 10 and 25 µg/ml. Samples were subjected to Tricine-SDS-PAGE and the blot was probed with R1 antibody.


Figure S6

Schematic representations of the data. A. A scheme of GPI PrP sequence, showing the PK-resistant areas (blue squares) and the PK cleavage points and flexible areas (gray line). B. Lengthwise comparison of the different peptides found by limited proteolysis and MALDI-TOF analysis (colors match those displayed in Figure 2).



We thank Bruce Chesebro, Rocky Mountain Laboratory, NIH, MT, USA, for his kind gift of GPI- mice, Hanna Serban, Institute for Neurodegenerative Diseases, UCSF, CA, USA, for generously providing antibody R1, Juan María Torres, CISA, Madrid, Spain, for RML inoculum, Valerie Sim, University of Alberta, Edmonton, Canada, for advice on GPI- PrPSc isolation and Melissa L. Erickson, USDA, for help in preparing the manuscript.

Funding Statement

This work was supported by EC grant FP7 222887 “Priority”. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.


1. Prusiner SB (1982) Novel proteinaceous infectious particles cause scrapie. Science 216: 136–144. [PubMed]
2. Prusiner SB (1998) Prions. Proc. Natl. Acad. Sci. U.S.A. 95: 13363–13383. [PubMed]
3. Harman JL, Silva CJ (2009) Bovine spongiform encephalopathy. J. Am. Vet. Med. Assoc. 234: 59–72. [PubMed]
4. López Garcia F, Zahn R, Riek R, Wüthrich K (2000) NMR structure of the bovine prion protein. Proc. Natl. Acad. Sci. U.S.A. 97: 8334–8339. [PubMed]
5. Knaus KJ, Morillas M, Swietnicki W, Malone M, Surewicz WK, et al. (2001) Crystal structure of the human prion protein reveals a mechanism for oligomerization. Nat. Struct. Biol. 8: 770–774. [PubMed]
6. McKinley MP, Bolton DC, Prusiner SB (1983) A protease-resistant protein is a structural component of the scrapie prion. Cell 35: 57–62. [PubMed]
7. Caughey BW, Dong A, Bhat KS, Ernst D, Hayes SF, et al. (1991) Secondary structure analysis of the scrapie-associated protein PrP 27–30 in water by infrared spectroscopy. Biochemistry 30: 7672–7680. [PubMed]
8. Baron GS, Hughson AG, Raymond GJ, Offerdahl DK, Barton KA, et al. (2011) Effect of glycans and the glycophosphatidylinositol anchor on strain dependent conformations of scrapie prion protein: improved purifications and infrared spectra. Biochemistry 50: 4479–4490. [PMC free article] [PubMed]
9. Smirnovas V, Baron GS, Offerdahl DK, Raymond GJ, Caughey B, et al. (2011) Structural organization of brain-derived mammalian prions examined by hydrogen-deuterium exchange. Nat. Struct. Mol. Biol. 18: 504–506. [PMC free article] [PubMed]
10. Govaerts C, Wille H, Prusiner SB, Cohen FE (2004) Evidence for assembly of prions with left-handed beta-helices into trimers. Proc. Natl. Acad. Sci. U.S.A. 101: 8342–8347. [PubMed]
11. Wille H, Michelitsch MD, Guenebaut V, Supattapone S, Serban A, et al. (2002) Structural studies of the scrapie prion protein by electron crystallography. Proc. Natl. Acad. Sci. U.S.A. 99: 3563–3568. [PubMed]
12. DeMarco ML, Daggett V (2004) From conversion to aggregation: protofibril formation of the prion protein. Proc. Natl. Acad. Sci. U.S.A. 101: 2293–2298. [PubMed]
13. Sajnani G, Pastrana MA, Dynin I, Onisko B, Requena JR (2008) Scrapie prion protein structural constraints obtained by limited proteolysis and mass spectrometry. J. Mol. Biol. 382: 88–98. [PubMed]
14. Hubbard SJ (1998) The structural aspects of limited proteolysis of native proteins. Biochim. Biophys. Acta 1382: 191–206. [PubMed]
15. Chesebro B, Trifilo M, Race R, Meade-White K, Teng C, et al. (2005) Anchorless prion protein results in infectious amyloid disease without clinical scrapie. Science 308: 1435–1439. [PubMed]
16. Chesebro B, Race B, Meade-White K, LaCasse R, Race R, et al. (2010) Fatal transmissible amyloid encephalopathy: a new type of prion disease associated with lack of prion protein membrane anchoring. PLoS Pathog. 6: e1000800. [PMC free article] [PubMed]
17. Schägger H (2006) Tricine-SDS-PAGE. Nat Protoc 1: 16–22. [PubMed]
18. Kocisko DA, Lansbury PT, Caughey B (1996) Partial unfolding and refolding of scrapie-associated prion protein: evidence for a critical 16-kDa C-terminal domain. Biochemistry 35: 13434–13442. [PubMed]
19. Zou W-Q, Capellari S, Parchi P, Sy M-S, Gambetti P, et al. (2003) Identification of novel proteinase K-resistant C-terminal fragments of PrP in Creutzfeldt-Jakob disease. J. Biol. Chem. 278: 40429–40436. [PubMed]
20. Zanusso G, Farinazzo A, Prelli F, Fiorini M, Gelati M, et al. (2004) Identification of distinct N-terminal truncated forms of prion protein in different Creutzfeldt-Jakob disease subtypes. J. Biol. Chem. 279: 38936–38942. [PubMed]
21. Bocharova OV, Breydo L, Salnikov VV, Gill AC, Baskakov IV (2005) Synthetic prions generated in vitro are similar to a newly identified subpopulation of PrPSc from sporadic Creutzfeldt-Jakob Disease. Protein Sci. 14: 1222–1232. [PubMed]
22. Makarava N, Kovacs GG, Savtchenko R, Alexeeva I, Budka H, et al. (2011) Genesis of mammalian prions: from non-infectious amyloid fibrils to a transmissible prion disease. PLoS Pathog. 7: e1002419. [PMC free article] [PubMed]
23. Notari S, Strammiello R, Capellari S, Giese A, Cescatti M, et al. (2008) Characterization of truncated forms of abnormal prion protein in Creutzfeldt-Jakob disease. J. Biol. Chem. 283: 30557–30565. [PubMed]
24. Stahl N, Baldwin MA, Teplow DB, Hood L, Gibson BW, et al. (1993) Structural studies of the scrapie prion protein using mass spectrometry and amino acid sequencing. Biochemistry 32: 1991–2002. [PubMed]
25. Sim VL, Caughey B (2009) Ultrastructures and strain comparison of under-glycosylated scrapie prion fibrils. Neurobiol. Aging 30: 2031–2042. [PubMed]
26. Jiménez JL, Guijarro JI, Orlova E, Zurdo J, Dobson CM, et al. (1999) Cryo-electron microscopy structure of an SH3 amyloid fibril and model of the molecular packing. EMBO J. 18: 815–821. [PubMed]
27. Wasmer C, Lange A, Van Melckebeke H, Siemer AB, Riek R, et al. (2008) Amyloid fibrils of the HET-s(218–289) prion form a beta solenoid with a triangular hydrophobic core. Science 319: 1523–1526. [PubMed]
28. Wille H, Bian W, McDonald M, Kendall A, Colby DW, et al. (2009) Natural and synthetic prion structure from X-ray fiber diffraction. Proc. Natl. Acad. Sci. U.S.A. 106: 16990–16995. [PubMed]
29. Wang F, Wang X, Yuan C-G, Ma J (2010) Generating a prion with bacterially expressed recombinant prion protein. Science 327: 1132–1135. [PMC free article] [PubMed]

Articles from PLoS ONE are provided here courtesy of Public Library of Science